Astrana Health’s first quarter was marked by progress in platform integration and the expansion of its AI-driven care model, leading to strong revenue growth and positive market reaction. Management credited the quarter’s momentum to disciplined growth in value-based care, successful integration of the Prospect acquisition, and increasing adoption of full-risk contracts. CEO Brandon Sim noted, “Our results increasingly reflect the advantages of the platform we have built and the way we are embedding AI across our platform.” The company also saw material operating leverage, with improvements in general and administrative efficiency and early returns from new risk-bearing arrangements.
Is now the time to buy ASTH? Find out in our full research report (it’s free for active Edge members).
Astrana Health (ASTH) Q1 CY2026 Highlights:
- Revenue: $965.1 million vs analyst estimates of $946.7 million (55.6% year-on-year growth, 1.9% beat)
- Adjusted EPS: $0.74 vs analyst estimates of $0.65 (13.8% beat)
- Adjusted EBITDA: $66.3 million vs analyst estimates of $64.94 million (6.9% margin, 2.1% beat)
- The company reconfirmed its revenue guidance for the full year of $3.95 billion at the midpoint
- EBITDA guidance for the full year is $265 million at the midpoint, below analyst estimates of $267 million
- Operating Margin: 3%, in line with the same quarter last year
- Market Capitalization: $2.22 billion
While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From Astrana Health’s Q1 Earnings Call
- Jack Slevin (Jefferies) asked about trends in Medicare Advantage and Medicaid enrollment versus expectations. CEO Brandon Sim outlined that Medicare enrollment showed mid-single-digit growth, Medicaid disenrollment was slightly higher than forecast, but overall trends were balanced by favorable acuity.
- Ryan Daniels (William Blair) inquired about further G&A efficiency opportunities from AI and commercialization of the Care Enablement platform. Sim detailed ongoing AI-driven workflow improvements and noted rapid growth and strong margins in the Care Enablement business.
- Jailendra Singh (Truist Securities) pressed on management’s confidence in reaching the 2027 EBITDA target following regulatory changes and recent performance. Sim emphasized the platform’s adaptability and reiterated belief in mid- to high-teens organic EBITDA growth.
- Craig Jones (Bank of America) questioned the impact of potential CMS risk adjustment model changes. Sim expressed that Astrana’s conservative, encounter-based approach positions it well for any shift toward AI-inferred risk scoring by regulators.
- Michael Ha (Baird) probed differences between Astrana’s AI-native platform and peers’ fragmented systems. Sim explained that Astrana’s internally built, unified data infrastructure enables comprehensive AI integration and is difficult for competitors to replicate.
Catalysts in Upcoming Quarters
In coming quarters, the StockStory team will focus on (1) tracking the pace of full-risk membership expansion and the maturation of these contracts, (2) monitoring incremental operating leverage from AI-enabled workflows and continued integration of Prospect, and (3) assessing the impact of regulatory developments on Medicare Advantage and Medicaid enrollment dynamics. Updates on new market entries, particularly in Texas, will also be important signposts.
Astrana Health currently trades at $40.00, up from $36.08 just before the earnings. In the wake of this quarter, is it a buy or sell? See for yourself in our full research report (it’s free).
The Best Stocks for High-Quality Investors
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662%. AppLovin before it ran 753%. Nvidia before it ran 1,178%. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.
